Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateUploadPipelinePE CyclesBrainAbout

Data updated weekly. Not financial advice.

Sector Alpha
  1. Home
  2. /Momentum
  3. /Hospitals/Medical Services
  4. /Gujarat Kidney & Super Speciality Ltd
MomentumDeep Value

Gujarat Kidney & Super Speciality Ltd: Stock Analysis & Fundamentals

Updated this week

Gujarat Kidney & Super Speciality Ltd (Hospitals/Medical Services) — fundamental analysis, earnings data, and key metrics. PE: 81.8. ROE: 51.2%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

📊Debt increased 135% YoY — leverage rising

Key Numbers

Current Price
₹102
Market Cap
805 Cr
Valuation
N/A

Other Top Hospitals/Medical Services Stocks Beating Nifty 500

Park Medi World Ltd
Weak
+49.1%
Nephrocare Health Services Ltd
Average
+21.7%
Unihealth Hospitals Ltd
Strong • 4w streak
+51.9%
← Back to Hospitals/Medical ServicesDashboard

Frequently Asked Questions: Gujarat Kidney & Super Speciality Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Gujarat Kidney & Super Speciality Ltd's latest quarterly results?

Gujarat Kidney & Super Speciality Ltd's latest quarterly results (Dec 2025) show

  • PAT Growth YoY: +46.2%
  • Revenue Growth YoY: +97.2%
  • Operating Margin: 29.7%

What is Gujarat Kidney & Super Speciality Ltd's current PE ratio?

Gujarat Kidney & Super Speciality Ltd's current PE ratio is 81.8x.

  • Current PE: 81.8x
  • Market Cap: 805 Cr

What is Gujarat Kidney & Super Speciality Ltd's price-to-book ratio?

Gujarat Kidney & Super Speciality Ltd's price-to-book ratio is 24.0x.

  • Price-to-Book (P/B): 24.0x
  • Book Value per Share: ₹4
  • Current Price: ₹102

Is Gujarat Kidney & Super Speciality Ltd a fundamentally strong company?

Gujarat Kidney & Super Speciality Ltd's fundamental strength based on key financial ratios

  • Return on Capital (ROCE): 51.5%

Is Gujarat Kidney & Super Speciality Ltd debt free?

Gujarat Kidney & Super Speciality Ltd has a debt-to-equity ratio of N/A.

  • Total Debt: ₹20 Cr

What is Gujarat Kidney & Super Speciality Ltd's return on equity (ROE) and ROCE?

Gujarat Kidney & Super Speciality Ltd's return ratios over recent years

  • FY2024: ROCE 19.3%
  • FY2025: ROCE 51.5%

Is Gujarat Kidney & Super Speciality Ltd's cash flow positive?

Gujarat Kidney & Super Speciality Ltd's operating cash flow is positive (FY2025).

  • Cash from Operations (CFO): ₹14 Cr
  • Free Cash Flow (FCF): ₹-5 Cr
  • CFO/PAT Ratio: 143% (strong cash conversion)

What is Gujarat Kidney & Super Speciality Ltd's dividend yield?

Gujarat Kidney & Super Speciality Ltd currently does not pay a significant dividend (yield 0.00%).

  • Dividend Yield: 0.00%
  • Current Price: ₹102

Who holds Gujarat Kidney & Super Speciality Ltd shares — promoters, FII, DII?

Gujarat Kidney & Super Speciality Ltd's shareholding pattern (Dec 2025)

  • Promoters: 71.5%
  • FII (Foreign): 10.5%
  • DII (Domestic): 1.7%
  • Public: 16.4%

Is Gujarat Kidney & Super Speciality Ltd a new momentum entry or an established outperformer?

Gujarat Kidney & Super Speciality Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Gujarat Kidney & Super Speciality Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Gujarat Kidney & Super Speciality Ltd may be worth studying

  • Cash flow is positive — CFO ₹14 Cr

What is the investment thesis for Gujarat Kidney & Super Speciality Ltd?

Gujarat Kidney & Super Speciality Ltd investment thesis summary:

What is the future outlook for Gujarat Kidney & Super Speciality Ltd?

Gujarat Kidney & Super Speciality Ltd's forward outlook based on current data signals

  • Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.